- Service Name
Seralutinib
- Industry
Biopharmaceutical, drug development, therapeutic products, pulmonary health
- Main Value Proposition
Seralutinib offers a novel therapeutic option for patients with pulmonary arterial hypertension and related conditions, aiming to enhance their quality of life.
- Description
Seralutinib is an investigational drug developed by Gossamer Bio for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It is designed to improve the lives of patients suffering from these rare diseases through innovative therapeutic approaches.
- Key Features
Inhaled PDGFRα/β, CSF1R, and c-KIT inhibitor; Designed for delivery via dry powder inhaler; Targeted treatment for PAH and PH-ILD; Phase 3 clinical research study (PROSERA Study)
- Use Cases
Treatment of pulmonary arterial hypertension (PAH); Management of pulmonary hypertension associated with interstitial lung disease (PH-ILD); Participation in clinical trials for new therapies
- Competitive advantages
Innovative inhaled formulation for direct lung delivery; Focus on rare diseases with significant unmet medical needs; Strong commitment to patient community and support
- Strengths
Gossamer Bio's dedication to developing differentiated therapeutic products and its commitment to improving patient lives are key strengths that enhance the appeal of Seralutinib.
- Positioning
Seralutinib positions itself as a cutting-edge treatment option in the biopharmaceutical market, specifically targeting rare pulmonary diseases.
- Audience
The primary audience includes patients suffering from PAH and PH-ILD, healthcare providers specializing in pulmonary diseases, and investors interested in biopharmaceutical innovations.
- CTA
Learn More
- Tags
pulmonary hypertension
biopharmaceutical
clinical trials
therapeutic innovation
- Tagline
A breath of new promise
- Tone of Voice
Professional, compassionate, innovative
- Differentiation
Seralutinib is unique in its inhaled delivery method and its specific targeting of multiple pathways involved in pulmonary hypertension, setting it apart from other treatments in the market.
- Brand Positioning
Gossamer Bio is positioned as a forward-thinking biopharmaceutical company dedicated to the discovery and development of novel therapies for rare diseases.
- Founded
2015-01-01
- Founders
Faheem Hasnain
Sheila Gujrathi